Product Description
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Korea | Lebanon | Russia
Approved Indications: None
Known Adverse Events: None
Company: CrystalGenomics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Osteoarthritis, Knee|Osteoarthritis, Hip
Phase 2: Osteoarthritis, Knee|Osteoarthritis, Hip|Osteoarthritis
Phase 1: Healthy Volunteers|Osteoarthritis|Hypertension|Anal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CG100651-1-01 | P1 |
Completed |
Healthy Volunteers |
2020-04-30 |
28% |
| CG100649-1-07 | P1 |
Completed |
Healthy Volunteers |
2019-05-03 |
28% |
| CG100650-1-01 | P1 |
Completed |
Healthy Volunteers |
2019-04-04 |
28% |
| CG100649-3-01 | P3 |
Completed |
Osteoarthritis, Knee|Osteoarthritis, Hip |
2013-12-01 |